$BIMI
BIMI Holdings Inc. Stock $bimi

$bimi Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000121390023096651 Filed on December 19, 2023

Income Statement

Concept	2023 Q3
Revenue	$2.523M
YoY Change	-65.51%
Cost Of Revenue	$2.408M
YoY Change	-57.98%
Gross Profit	$115.2K
YoY Change	-92.73%
Gross Profit Margin	4.56%
Selling, General & Admin	$3.265M
YoY Change	-30.19%
% of Gross Profit	2835.18%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	-$18.75K
YoY Change	-147.52%
% of Gross Profit	-16.28%
Operating Expenses	$3.265M
YoY Change	-30.19%
Operating Profit	-$3.150M
YoY Change	1.86%
Interest Expense	$35.88K
YoY Change	-63.16%
% of Operating Profit
Other Income/Expense, Net	$15.62K
YoY Change	-102.51%
Pretax Income	-$3.134M
YoY Change	-15.63%
Income Tax
% Of Pretax Income
Net Earnings	-$3.129M
YoY Change	-15.72%
Net Earnings / Revenue	-124.02%
Basic Earnings Per Share	-$0.51
Diluted Earnings Per Share	-$0.51
COMMON SHARES
Basic Shares Outstanding	6.430M shares
Diluted Shares Outstanding	6.430M shares

Balance Sheet

Concept	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$994.1K
YoY Change	-5.04%
Cash & Equivalents	$994.1K
Short-Term Investments
Other Short-Term Assets	$12.15M
YoY Change	114.34%
Inventory	$7.087M
Prepaid Expenses
Receivables	$4.116M
Other Receivables	$19.78K
Total Short-Term Assets	$24.37M
YoY Change	40.17%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.672M
YoY Change	-42.04%
Goodwill	$2.066M
YoY Change	-75.34%
Intangibles	$468.2K
YoY Change	2849.24%
Long-Term Investments
YoY Change
Other Assets	$3.561M
YoY Change	871.86%
Total Long-Term Assets	$10.67M
YoY Change	-31.66%
TOTAL ASSETS
Total Short-Term Assets	$24.37M
Total Long-Term Assets	$10.67M
Total Assets	$35.04M
YoY Change	6.17%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$10.44M
YoY Change	146.65%
Accrued Expenses	$3.561M
YoY Change	12.11%
Deferred Revenue
YoY Change
Short-Term Debt	$1.137M
YoY Change	-17.8%
Long-Term Debt Due	$135.8K
YoY Change	-25.87%
Total Short-Term Liabilities	$20.16M
YoY Change	6.66%
LONG-TERM LIABILITIES
Long-Term Debt	$24.37K
YoY Change	-94.87%
Other Long-Term Liabilities	$4.717M
YoY Change	37.96%
Total Long-Term Liabilities	$4.741M
YoY Change	21.76%
TOTAL LIABILITIES
Total Short-Term Liabilities	$20.16M
Total Long-Term Liabilities	$4.741M
Total Liabilities	$24.90M
YoY Change	9.24%
SHAREHOLDERS EQUITY
Retained Earnings	-$71.43M
YoY Change
Common Stock	$6.673K
YoY Change	-99.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$8.707M
YoY Change
Total Liabilities & Shareholders Equity	$35.04M
YoY Change	6.17%

Cashflow Statement

Concept	2023 Q3
OPERATING ACTIVITIES
Net Income	-$3.129M
YoY Change	-15.72%
Depreciation, Depletion And Amortization	-$18.75K
YoY Change	-147.52%
Cash From Operating Activities	-$1.486M
YoY Change	-82.06%
INVESTING ACTIVITIES
Capital Expenditures	$603.9K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00
YoY Change	-100.0%
Cash From Investing Activities	-$603.9K
YoY Change	235.49%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.036M
YoY Change	-77.91%
NET CHANGE
Cash From Operating Activities	-1.486M
Cash From Investing Activities	-603.9K
Cash From Financing Activities	1.036M
Net Change In Cash	-1.054M
YoY Change	-72.08%
FREE CASH FLOW
Cash From Operating Activities	-$1.486M
Capital Expenditures	$603.9K
Free Cash Flow	-$2.090M
YoY Change	-74.77%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.49
CY2022Q4	us-gaap	Liabilities Liabilities	28877257	usd
CY2023Q3	us-gaap	Common Stock Value CommonStockValue	6673	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	3765	usd
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.51
CY2022Q4	bimi	Operating Lease Right Of Use Asset Total OperatingLeaseRightOfUseAssetTotal	2942265	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2907606	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	2942265	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	726309	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	532630	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2447060	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	3173369	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	3107381	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2023Q3	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax		usd
	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax		usd
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24037736	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	36395729	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4967278	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6429980	shares
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.04
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.05
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.11
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.28
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.51
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.55
	us-gaap	Share Based Compensation ShareBasedCompensation		usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium		usd
	us-gaap	Goodwill Impairment Loss Net Of Tax GoodwillImpairmentLossNetOfTax		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-50155
	dei	Entity Registrant Name EntityRegistrantName	BIMI International Medical Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	02-0563302
	dei	Entity Address Address Line1 EntityAddressAddressLine1	725 5th Avenue
	dei	Entity Address Address Line2 EntityAddressAddressLine2	15th Floor
	dei	Entity Address Address Line3 EntityAddressAddressLine3	Suite 15-01
	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	400010
	dei	City Area Code CityAreaCode	212
	dei	Local Phone Number LocalPhoneNumber	542 0028
	dei	Security12b Title Security12bTitle	Common Stock, $0.001 par value
	dei	Trading Symbol TradingSymbol	BIMI
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	11589569	shares
CY2023Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	994131	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2336636	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4115964	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3208286	usd
CY2023Q3	us-gaap	Supplies Supplies	8737956	usd
CY2022Q4	us-gaap	Supplies Supplies	6589759	usd
CY2023Q3	us-gaap	Other Receivables OtherReceivables	6964	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	7086791	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	7654242	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1278336	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1527079	usd
CY2023Q3	bimi	Current Assets From Discontinued Operationsheld For Sale CurrentAssetsFromDiscontinuedOperationsheldForSale	2147050	usd
CY2022Q4	bimi	Current Assets From Discontinued Operationsheld For Sale CurrentAssetsFromDiscontinuedOperationsheldForSale	2099673	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	24367192	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	23415675	usd
CY2023Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	184433	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	190132	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1671628	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1703420	usd
CY2023Q3	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	468163	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock		usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	16183	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2907606	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	2942265	usd
CY2023Q3	us-gaap	Goodwill Goodwill	2065666	usd
CY2022Q4	us-gaap	Goodwill Goodwill	2065666	usd
CY2023Q3	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	3376261	usd
CY2022Q4	us-gaap	Disposal Group Including Discontinued Operation Assets Noncurrent DisposalGroupIncludingDiscontinuedOperationAssetsNoncurrent	3761149	usd
CY2023Q3	us-gaap	Assets Noncurrent AssetsNoncurrent	10673757	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	10678815	usd
CY2023Q3	us-gaap	Assets Assets	35040949	usd
CY2022Q4	us-gaap	Assets Assets	34094490	usd
CY2023Q3	us-gaap	Short Term Borrowings ShortTermBorrowings	1136522	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	818425	usd
CY2023Q3	us-gaap	Loans Payable Current LoansPayableCurrent	135809	usd
CY2022Q4	us-gaap	Loans Payable Current LoansPayableCurrent	105965	usd
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1108785	usd
CY2023Q3	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	10438404	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	10785531	usd
CY2023Q3	bimi	Advances From Customers AdvancesFromCustomers	761759	usd
CY2022Q4	bimi	Advances From Customers AdvancesFromCustomers	923131	usd
CY2023Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	26800	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	71915	usd
CY2023Q3	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	3265456	usd
CY2022Q4	us-gaap	Other Accounts Payable And Accrued Liabilities OtherAccountsPayableAndAccruedLiabilities	3175574	usd
CY2023Q3	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	726309	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	532630	usd
CY2023Q3	bimi	Current Liabilities From Discontinued Operationsheld For Sale CurrentLiabilitiesFromDiscontinuedOperationsheldForSale	3143243	usd
CY2022Q4	bimi	Current Liabilities From Discontinued Operationsheld For Sale CurrentLiabilitiesFromDiscontinuedOperationsheldForSale	3239950	usd
CY2023Q3	us-gaap	Liabilities Current LiabilitiesCurrent	20158497	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	23742347	usd
CY2023Q3	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2447060	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2574751	usd
CY2023Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	24374	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	314786	usd
CY2023Q3	bimi	Noncurrent Liabilities From Discontined Operationsheld For Sale NoncurrentLiabilitiesFromDiscontinedOperationsheldForSale	2269672	usd
CY2022Q4	bimi	Noncurrent Liabilities From Discontined Operationsheld For Sale NoncurrentLiabilitiesFromDiscontinedOperationsheldForSale	2245373	usd
CY2023Q3	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	4741106	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	5134910	usd
CY2023Q3	us-gaap	Liabilities Liabilities	24899603	usd
CY2023Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	200000000	shares
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6673006	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6673006	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3764780	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3764780	shares
CY2023Q3	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	78997594	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	71899271	usd
CY2023Q3	bimi	Statutory Reserves StatutoryReserves	2263857	usd
CY2022Q4	bimi	Statutory Reserves StatutoryReserves	2263857	usd
CY2023Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-71429357	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-70143785	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-1132206	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	24583	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	8706561	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	4047691	usd
CY2023Q3	us-gaap	Minority Interest MinorityInterest	1434785	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	1169542	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10141346	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5217233	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35040949	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	34094490	usd
CY2023Q3	us-gaap	Revenues Revenues	2523193	usd
CY2022Q3	us-gaap	Revenues Revenues	4932479	usd
	us-gaap	Revenues Revenues	11278496	usd
	us-gaap	Revenues Revenues	10476224	usd
CY2023Q3	us-gaap	Cost Of Revenue CostOfRevenue	2408038	usd
CY2022Q3	us-gaap	Cost Of Revenue CostOfRevenue	4229316	usd
	us-gaap	Cost Of Revenue CostOfRevenue	6589020	usd
	us-gaap	Cost Of Revenue CostOfRevenue	8928138	usd
CY2023Q3	us-gaap	Gross Profit GrossProfit	115155	usd
CY2022Q3	us-gaap	Gross Profit GrossProfit	703163	usd
	us-gaap	Gross Profit GrossProfit	4689476	usd
	us-gaap	Gross Profit GrossProfit	1548086	usd
CY2023Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	171763	usd
CY2022Q3	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	310475	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	664076	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	952102	usd
CY2023Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3093088	usd
CY2022Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2805211	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5220553	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	7924995	usd
CY2023Q3	us-gaap	Operating Expenses OperatingExpenses	3264851	usd
CY2022Q3	us-gaap	Operating Expenses OperatingExpenses	3115686	usd
	us-gaap	Operating Expenses OperatingExpenses	5884629	usd
	us-gaap	Operating Expenses OperatingExpenses	8877097	usd
CY2023Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-3149696	usd
CY2022Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-2412523	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-1195153	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-7329011	usd
CY2023Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	53	usd
CY2022Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	263	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	379	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	616	usd
CY2023Q3	us-gaap	Interest Expense InterestExpense	35877	usd
CY2022Q3	us-gaap	Interest Expense InterestExpense	35038	usd
	us-gaap	Interest Expense InterestExpense	105407	usd
	us-gaap	Interest Expense InterestExpense	131756	usd
CY2023Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-1338	usd
CY2022Q3	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	7427	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-3622	usd
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	991	usd
CY2022Q3	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-771124	usd
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium	-2313372	usd
CY2023Q3	us-gaap	Gain Loss On Sale Of Stock In Subsidiary Or Equity Method Investee GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee	107101	usd
	us-gaap	Gain Loss On Sale Of Stock In Subsidiary Or Equity Method Investee GainLossOnSaleOfStockInSubsidiaryOrEquityMethodInvestee	304840	usd
CY2023Q3	bimi	Nonoperating Incomeexpenses NonoperatingIncomeexpenses	-54315	usd
CY2022Q3	bimi	Nonoperating Incomeexpenses NonoperatingIncomeexpenses	101498	usd
	bimi	Nonoperating Incomeexpenses NonoperatingIncomeexpenses	-147618	usd
	bimi	Nonoperating Incomeexpenses NonoperatingIncomeexpenses	-2511520	usd
CY2022Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	8886	usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome	75606	usd
CY2023Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	15624	usd
CY2022Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-688088	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	48572	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-4879435	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3134072	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-3100611	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-1146581	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12208446	usd
CY2022Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-949	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	6202	usd
CY2023Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-3134072	usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-3099662	usd
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-1146581	usd
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-12214648	usd
CY2023Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-116718	usd
CY2022Q3	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-758465	usd
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-259820	usd
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-957203	usd
CY2022Q3	us-gaap	Discontinued Operation Gain Loss On Disposal Of Discontinued Operation Net Of Tax DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax	-26928	usd
CY2023Q3	us-gaap	Profit Loss ProfitLoss	-3250790	usd
CY2022Q3	us-gaap	Profit Loss ProfitLoss	-3885055	usd
	us-gaap	Profit Loss ProfitLoss	-1406401	usd
	us-gaap	Profit Loss ProfitLoss	-13171851	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-121545	usd
CY2022Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-1450	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-120830	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3948	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	-3129245	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	-3883605	usd
	us-gaap	Net Income Loss NetIncomeLoss	-1285571	usd
	us-gaap	Net Income Loss NetIncomeLoss	-13167903	usd
CY2023Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-630330	usd
CY2022Q3	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-399821	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1156789	usd
	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax	-1367407	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-3881120	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-4284876	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-2563190	usd
	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-14539258	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	190783	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-487621	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-1317844	usd
	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-1022664	usd
CY2023Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-4071903	usd
CY2022Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3797255	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1245346	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13516594	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6429980	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	36395729	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4967278	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	24037736	shares
CY2023Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.49
CY2022Q3	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.09
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.23
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.51
CY2023Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.02
CY2022Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.02
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.05
	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Basic Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare	-0.04
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.51
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.11
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.28
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.55
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	5217233	usd
CY2023Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	376607	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	789992	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	3301636	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-3186276	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	6499192	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	5143985	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	1054397	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-106449	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-78629	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	12512496	usd
CY2023Q3	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	1580639	usd
CY2023Q3	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	-3250790	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-623374	usd
CY2023Q3	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	-77625	usd
CY2023Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10141346	usd
	us-gaap	Profit Loss ProfitLoss	-1406401	usd
	us-gaap	Profit Loss ProfitLoss	-13171851	usd
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-259820	usd
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Before Income Tax DiscontinuedOperationIncomeLossFromDiscontinuedOperationBeforeIncomeTax	-957203	usd
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-1146581	usd
	us-gaap	Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest	-12214648	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	111252	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	86111	usd
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	2394843	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2339963	usd
	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	2313372	usd
	us-gaap	Gain Or Loss On Sale Of Stock In Subsidiary GainOrLossOnSaleOfStockInSubsidiary	-304840	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3302521	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-414102	usd
	bimi	Increase Decrease In Advances To Suppliers IncreaseDecreaseInAdvancesToSuppliers	-1937809	usd
	bimi	Increase Decrease In Advances To Suppliers IncreaseDecreaseInAdvancesToSuppliers	-5417687	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-248743	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-145802	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-567451	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1287095	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-34659	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-305999	usd
	bimi	Increase Decrease In Other Account Payable IncreaseDecreaseInOtherAccountPayable	-347127	usd
	bimi	Increase Decrease In Other Account Payable IncreaseDecreaseInOtherAccountPayable	-3042294	usd
	bimi	Increase Decrease I Advances From Customers IncreaseDecreaseIAdvancesFromCustomers	-161372	usd
	bimi	Increase Decrease I Advances From Customers IncreaseDecreaseIAdvancesFromCustomers	-375390	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	65988	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-286203	usd
	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	-39416	usd
	us-gaap	Increase Decrease In Income Taxes IncreaseDecreaseInIncomeTaxes	-232187	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	89882	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1695774	usd
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	758450	usd
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-5536365	usd
	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	5283	usd
	us-gaap	Net Cash Provided By Used In Discontinued Operations NetCashProvidedByUsedInDiscontinuedOperations	-1054953	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	763733	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6591318	usd
	us-gaap	Payments To Acquire Land Held For Use PaymentsToAcquireLandHeldForUse	180000	usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	603892	usd
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-603892	usd
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-180000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-603892	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-180000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	5000000	usd
	bimi	Net Proceeds From Stock Purchase NetProceedsFromStockPurchase	1600000	usd
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	1600	usd
	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	318097	usd
	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	112679	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt And Capital Securities Net ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet	29844	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	290412	usd
	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	366315	usd
	bimi	Amounts Financed From Byrepaid To Related Parties AmountsFinancedFromByrepaidToRelatedParties	2463210	usd
	bimi	Amounts Financed From Byrepaid To Related Parties AmountsFinancedFromByrepaidToRelatedParties	254768	usd
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	-804081	usd
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	4491596	usd
	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations	-333686	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-804081	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4157910	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-698265	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	-995684	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-1342505	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-3609092	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	2336636	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	4609431	usd
CY2023Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	994131	usd
CY2022Q3	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	1000339	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	217837	usd
	us-gaap	Interest Paid Net InterestPaidNet	64861	usd
	us-gaap	Interest Paid Net InterestPaidNet	87425	usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	15531	usd
	bimi	Issuance Of Common Stock Upon Conversion Of Convertible Notes IssuanceOfCommonStockUponConversionOfConvertibleNotes	1308	usd
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	39875	usd
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	44826	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><b>1. ORGANIZATION AND BUSINESS BACKGROUND</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">BIMI International Medical, Inc. (the “Company” or “BIMI”) was incorporated in the State of Delaware as Galli Process, Inc. on October 31, 2000. On February 7, 2002, the Company changed its name to Global Broadcast Group, Inc. On November 12, 2004, the Company changed its name to Diagnostic Corporation of America. On March 15, 2007, the Company changed its name to NF Energy Saving Corporation of America, and on August 24, 2009, the Company changed its name to NF Energy Saving Corporation. On December 16, 2019, the Company changed its name to BOQI International Medical Inc., to reflect the Company’s refocus of its business from the energy saving industry to the health care industry and on June 21, 2021, we changed our name to BIMI International Medical Inc. Since March 7, 2012, the Common Stock of the Company (the “Common Stock”) has been traded on the Nasdaq Capital Market.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Until October 14, 2019, the Company, through NF Energy Saving Investment Limited and its subsidiaries (the “NF Group”), operated in the energy saving enhancement technology industry in the People’s Republic of China (the “PRC”). The NF Group focused on providing services relating to energy saving technology, optimization design, energy saving reconstruction of pipeline networks and contractual energy management for the electric power, petrochemical, coal, metallurgy, construction, and municipal infrastructure development industries in the PRC and the manufacture and sales of energy-saving flow control equipment. In late 2019, the Company committed to a plan to dispose of all its equity interests in the NF Group and on March 31, 2020, the Company entered into a stock purchase agreement (the “NF SPA”) to sell the NF Group. The sale of the NF Group closed on June 23, 2020.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On October 14, 2019, the Company acquired 100% of the equity interests in Lasting Wisdom Holdings Limited (“Lasting”), a limited company incorporated under the laws of the British Virgin Islands (“BVI”). Lasting has limited operating activities since incorporation except for holding the ownership interest in Pukung Limited (“Pukung”), a company organized under the laws of Hong Kong. Pukung owns 100% of the equity interest in Beijing Xinrongxin Industrial Development Co., Ltd. (“Xinrongxin”), a company organized under the laws of the PRC. Xinrongxin owns all the ownership interest of Dalian Boqi Zhengji Pharmacy Chain Co., Ltd. (“Boqi Zhengji”). Boqi Zhengji operated 16 retail pharmacy stores in China at the time of the acquisition. Lasting, Pukung, Xinrongxin and Boqi Zhengji are hereinafter collectively referred to as the “Boqi Zhengji Group”. Xinrongxin also owns 100% equity interests in Dalian Boyi Technology Co., Ltd. (“Dalian Boyi”), a subsidiary established in January 2020 and responsible for the Company’s R&D and other technology related functions.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On June 24, 2020, the Company established a wholly owned subsidiary Boyi (Liaoning) Technology Co.,Ltd (“Liaoning Boyi”), in order to be qualified to participate in local healthcare projects. On December 22, 2020, the Company established another subsidiary, Bimai Pharmaceutical (Chongqing) Co., Ltd., to replace Xinronxin as the holding company owning all the retail, wholesale and hospital operations in China.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On March 18, 2020, the Company, through its wholly owned subsidiary, Xinrongxin, acquired 100% of the equity interests in Chongqing Guanzan Technology Co., Ltd. (“Guanzan”). Guanzan held an 80% equity interest in Chongqing Shude Pharmaceutical Co., Ltd. (“Shude”, and collectively with Guanzan, the “Guanzan Group”). Guanzan also owns 100% equity interest in Chongqing Lijiantang Pharmaceutical Co. Ltd., a subsidiary established in May 2020. Lijiantang operates 4 retail pharmacy stores in China (collectively, the “Lijiantang Pharmacy Group”). </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 11, 2020, the Company entered into a stock purchase agreement to sell Boqi Zhengji. The sale of the Boqi Zhengji closed by the end of 2020 although the government record was not updated until February 2, 2021 due to the Chinese government’s alternative working schedule and other delays caused by COVID-19.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 9, 2020, the Company entered into an agreement to acquire 100% of the equity interests in Chongqing Guoyitang Hospital (“Guoyitang”), the owner and operator of a private general hospital in Chongqing City, a city in Southwest China. The transaction closed on February 2, 2021. </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 15, 2020, the Company entered into an agreement to acquire Chaohu Zhongshan Minimally Invasive Hospital (“Zhongshan”), a private hospital in the Southeast region of China. The transaction closed on February 5, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 9, 2021, the Company entered into an agreement to acquire three private hospitals in the PRC, Wuzhou Qiangsheng Hospital (“Qiangsheng”), Suzhou Eurasia Hospital(“Eurasia”) and Yunnan Yuxi MinKang hospital (“Minkang”). The transaction closed on May 6, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 21, 2021, Bimai Hospital Management (Chongqing) Co. Ltd. was incorporated in the PRC by the Company to manage the operations of the Company’s medical services segment.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On April 21, 2021, Pusheng Pharmaceutical Co., Ltd. was incorporated in the PRC by the Company to manage its wholesale distribution of generic drugs.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On September 10, 2021, the Company entered into an agreement to acquire 100% of the equity interests in Chongqing Zhuoda Pharmaceutical Co., LTD (“Zhuoda”). The transaction closed on October 8, 2021.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">On December 20, 2021, the Company entered into a stock purchase agreement to acquire Bengbu Mali OB-GYN Hospital Co., Ltd. (“Mali Hospital”). We agreed to purchase all the issued and outstanding equity interests in Mali Hospital in consideration of $16,750,000. At the signing, 60,000 shares of the Company’s Common Stock (reflecting the Reverse Splits) were delivered as partial consideration for the purchase and on January 4, 2022, we paid RMB 7,227,000 to the seller as partial consideration. The transaction did not close and on December 15, 2022, we entered into a termination agreement with respect to the original purchase agreement. Pursuant to the termination agreement, the original agreement will terminate effective as of the date of the return of the 60,000 shares of the Company’s Common Stock (reflecting the Reverse Splits) previously issued to the sellers and certain third-party beneficiaries. On December 9, 2022, 52,000 shares of Common Stock were returned to the Company and on September 1, 2023, the remaining 8,000 shares of Common Stock were returned to the Company. All cash paid at the time of the acquisition is expected to be returned by December 31, 2023.<b> </b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p> <p style="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; background-color: white">On July 5, 2022, we entered into a stock purchase agreement (as amended on February 27, 2023) with Mr. Fnu Oudom, the Chairman of our board of directors, whereby we agreed to acquire 100% of the equity interests in Phenix Bio Inc. (“Phenix”), a developer and distributor of dietary supplements, in consideratio</span><span style="font-family: Times New Roman, Times, Serif">n of $1,800,000. The transaction closed effective March 15, 2023. The aggregate purchase price for the equity interests in Phenix was $180,000 in cash, which was paid on July 7, 2022, plus up to 5,270,000 shares of the Company’s Common Stock (reflecting the Reverse Splits), of which 270,000 shares were issued to Mr. Oudom on June 19, 2023, after shareholder approval was obtained. We agreed to issue 5,000,000 shares of Common Stock to Mr. Oudom in the event that Phenix will generate at least $2,500,000 in net profit in calendar year 2023 or in any fiscal quarter of 2023.</span> Such performance target was met in the second quarter of 2023 and the 5,000,000 shares were issued to Mr. Oudom on December 6, 2023.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2023, the Company has four operating segments: retail pharmacy, wholesale pharmaceuticals, wholesale medical devices and healthcare products.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.05pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The retail pharmacy segment engages in the retail sale of medicine and other healthcare products in the PRC. The retail pharmacy segment sells its medicine and other healthcare products to customers through its directly owned stores. The group offers a wide range of products, including prescription and over the counter (“OTC”) drugs, nutritional supplements, traditional Chinese medicines, personal and family care products and medical devices, as well as miscellaneous items.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.05pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s wholesale segments are engaged in the distribution of medical devices and pharmaceuticals. The wholesale medical devices segment distributes medical devices, including medical consumables to drug stores, private clinics, pharmaceutical dealers, and hospitals. The wholesale pharmaceuticals segment supplies prescription and OTC medicines, TCM, healthcare supplies and sundry items to clinics, third party pharmacies, hospitals, and other drug vendors.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.05pt; text-align: justify"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The Company’s healthcare products are <span style="background-color: white">developed</span> and distributed by Phenix. Phenix owns its formulas and uses out-sourced facilities in the U.S. and Australia to manufacture its products. To date, Phenix has sold all of its products through Meta Time, an online sales platform. Most of the customers were from Asian countries. Phenix currently offers six categories of dietary supplements, a cardiovascular product, an anti-insomnia and depression product, a male aphrodisiac product, a woman’s menopausal syndrome product, a gout product, and an immunity enhancer.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">As of September 30, 2022, the Company had four operating segments: wholesale medical devices, wholesale pharmaceuticals, medical services, and retail pharmacy.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 9.05pt; text-align: justify"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="text-decoration:underline">As of September 30, 2023, the details of the Company’s subsidiaries are as <span style="background-color: white">follows</span></span><span style="background-color: white">:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p> <table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="border-bottom: Black 1.5pt solid; text-align: left; font-weight: bold; vertical-align: bottom">Name</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Place of incorporation and<br/> kind of legal entity</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; vertical-align: bottom; font-weight: bold; text-align: center">Principal activities and<br/> Type of operation</td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">Effective<br/> ownership interest held</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; width: 28%; text-align: left; text-indent: -9pt; padding-left: 9pt">Lasting Wisdom Holdings Limited (“Lasting”)</td><td style="width: 1%"> </td> <td style="vertical-align: top; width: 29%; text-align: left">British Virgin Island, a limited liability company</td><td style="width: 1%"> </td> <td style="vertical-align: top; width: 29%; text-align: left">Investment holding</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 9%; text-align: right">100</td><td style="width: 1%; text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt; vertical-align: top"> </td><td> </td> <td style="text-align: left; vertical-align: top"> </td><td> </td> <td style="text-align: left; vertical-align: top"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Phenix Bio Inc. (“Phenix”)</td><td> </td> <td style="vertical-align: top; text-align: left">California, a corporation</td><td> </td> <td style="vertical-align: top; text-align: left">Distribution of healthcare products</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt; vertical-align: top"> </td><td> </td> <td style="text-align: left; vertical-align: top"> </td><td> </td> <td style="text-align: left; vertical-align: top"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Pukung Limited (“Pukung”)</td><td> </td> <td style="vertical-align: top; text-align: left">Hong Kong, a limited liability company</td><td> </td> <td style="vertical-align: top; text-align: left">Investment holding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt; vertical-align: top"> </td><td> </td> <td style="text-align: left; vertical-align: top"> </td><td> </td> <td style="text-align: left; vertical-align: top"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Chongqing Guanzan Technology Co., Ltd. (“Guanzan”)</td><td> </td> <td style="vertical-align: top; text-align: left">The PRC, a limited liability company</td><td> </td> <td style="vertical-align: top; text-align: left">Wholesale distribution of medical devices in the PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt; vertical-align: top"> </td><td> </td> <td style="text-align: left; vertical-align: top"> </td><td> </td> <td style="text-align: left; vertical-align: top"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Chongqing Shude Pharmaceutical Co., Ltd.(“Shude”)</td><td> </td> <td style="vertical-align: top; text-align: left">The PRC, a limited liability company</td><td> </td> <td style="vertical-align: top; text-align: left">Wholesale distribution of generic drugs in the PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">95</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt; vertical-align: top"> </td><td> </td> <td style="text-align: left; vertical-align: top"> </td><td> </td> <td style="text-align: left; vertical-align: top"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Chongqing Lijiantang Pharmaceutical Co., Ltd.(“Lijiantang”)</td><td> </td> <td style="vertical-align: top; text-align: left">The PRC, a limited liability company</td><td> </td> <td style="vertical-align: top; text-align: left">Wholesale distribution of generic drugs in the PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt; vertical-align: top"> </td><td> </td> <td style="text-align: left; vertical-align: top"> </td><td> </td> <td style="text-align: left; vertical-align: top"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Bimai Pharmaceutical (Chongqing) Co., Ltd.</td><td> </td> <td style="vertical-align: top; text-align: left">The PRC, a limited liability company</td><td> </td> <td style="vertical-align: top; text-align: left">Investment holding</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt; vertical-align: top"> </td><td> </td> <td style="text-align: left; vertical-align: top"> </td><td> </td> <td style="text-align: left; vertical-align: top"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Chongqing Guoyitang Hospital Co., Ltd.</td><td> </td> <td style="vertical-align: top; text-align: left">The PRC, a limited liability company</td><td> </td> <td style="vertical-align: top; text-align: left">Hospital in the PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt; vertical-align: top"> </td><td> </td> <td style="text-align: left; vertical-align: top"> </td><td> </td> <td style="text-align: left; vertical-align: top"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Chongqing Huzhongtang Healthy Technology Co., Ltd.</td><td> </td> <td style="vertical-align: top; text-align: left">The PRC, a limited liability company</td><td> </td> <td style="vertical-align: top; text-align: left">Wholesale distribution of generic drugs in the PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt; vertical-align: top"> </td><td> </td> <td style="text-align: left; vertical-align: top"> </td><td> </td> <td style="text-align: left; vertical-align: top"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Chaohu Zhongshan Minimally Invasive Hospital Co.,Ltd.</td><td> </td> <td style="vertical-align: top; text-align: left">The PRC, a limited liability company</td><td> </td> <td style="vertical-align: top; text-align: left">Hospital in the PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt; vertical-align: top"> </td><td> </td> <td style="text-align: left; vertical-align: top"> </td><td> </td> <td style="text-align: left; vertical-align: top"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Yunnan Yuxi Minkang Hospital Co., Ltd.</td><td> </td> <td style="vertical-align: top; text-align: left">The PRC, a limited liability company</td><td> </td> <td style="vertical-align: top; text-align: left">Hospital in the PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt; vertical-align: top"> </td><td> </td> <td style="text-align: left; vertical-align: top"> </td><td> </td> <td style="text-align: left; vertical-align: top"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Wuzhou Qiangsheng Hospital Co., Ltd.</td><td> </td> <td style="vertical-align: top; text-align: left">The PRC, a limited liability company</td><td> </td> <td style="vertical-align: top; text-align: left">Hospital in the PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt; vertical-align: top"> </td><td> </td> <td style="text-align: left; vertical-align: top"> </td><td> </td> <td style="text-align: left; vertical-align: top"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Suzhou Eurasia Hospital Co., Ltd.</td><td> </td> <td style="vertical-align: top; text-align: left">The PRC, a limited liability company</td><td> </td> <td style="vertical-align: top; text-align: left">Hospital in the PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt; vertical-align: top"> </td><td> </td> <td style="text-align: left; vertical-align: top"> </td><td> </td> <td style="text-align: left; vertical-align: top"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Bimai Hospital Management (Chongqing) Co. Ltd</td><td> </td> <td style="vertical-align: top; text-align: left">The PRC, a limited liability company</td><td> </td> <td style="vertical-align: top; text-align: left">Hospital management in the PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt; vertical-align: top"> </td><td> </td> <td style="text-align: left; vertical-align: top"> </td><td> </td> <td style="text-align: left; vertical-align: top"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="vertical-align: top; text-align: left; text-indent: -9pt; padding-left: 9pt">Pusheng Pharmaceutical Co., Ltd</td><td> </td> <td style="vertical-align: top; text-align: left">The PRC, a limited liability company</td><td> </td> <td style="vertical-align: top; text-align: left">Wholesale distribution of generic drugs in the PRC</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">100</td><td style="text-align: left">%</td></tr> </table>
CY2021Q4	us-gaap	Interest And Fee Income Loans Consumer Home Equity InterestAndFeeIncomeLoansConsumerHomeEquity	16750000	usd
CY2022Q1	bimi	Purchased Common Stock Shares PurchasedCommonStockShares	60000	shares
CY2022Q1	us-gaap	Interest And Fee Income Loans Consumer Home Equity InterestAndFeeIncomeLoansConsumerHomeEquity	7227000	cny
CY2022Q4	bimi	Common Stock Shares Not Received CommonStockSharesNotReceived	52000	shares
CY2023Q3	bimi	Cash Considerations Amount CashConsiderationsAmount	8000	shares
CY2023Q3	bimi	Consideration Amount ConsiderationAmount	1800000	usd
CY2023Q3	us-gaap	Temporary Equity Accretion Of Interest TemporaryEquityAccretionOfInterest	180000	usd
CY2023Q3	us-gaap	Stock Issued During Period Shares Other StockIssuedDuringPeriodSharesOther	5270000	shares
CY2023Q3	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	270000	shares
CY2023Q3	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	2500000	usd
CY2023Q4	us-gaap	Shares Issued SharesIssued	5000000	shares
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	4	pure
	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	4	pure
	us-gaap	Other Operating Income OtherOperatingIncome	1406401	usd
	us-gaap	Other Operating Income OtherOperatingIncome	13171851	usd
CY2023Q3	us-gaap	Finance Lease Right Of Use Asset FinanceLeaseRightOfUseAsset	71400000	usd
CY2022Q2	us-gaap	Subordinated Debt SubordinatedDebt	5000000	usd
CY2022Q2	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	1250000	shares
	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1 to 10 reverse split
CY2022Q3	us-gaap	Deposit Assets DepositAssets	180000	usd
CY2022Q4	us-gaap	Cash Cash	6116207	usd
CY2023Q3	us-gaap	Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased	1000	shares
	us-gaap	Dividends Cash DividendsCash	3055	usd
	us-gaap	Use Of Estimates UseOfEstimates	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: top"> <td style="width: 24px; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Use of estimates</b></span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">The preparation of these condensed consolidated financial statements in conformity with the US GAAP requires management to make estimates and judgments that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities on the date of these condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. The Company bases its estimates and judgments on historical experience and on various other assumptions and information that are believed to be reasonable under the circumstances. Estimates and assumptions of future events and their effects cannot be perceived with certainty and, accordingly, these estimates may change as new events occur, as more experience is acquired, as additional information is obtained and as our operating environment changes. Significant estimates and assumptions made by management include, among others, useful lives and impairment of long-lived assets, collectability of accounts receivable, advances to suppliers, allowance for doubtful accounts, reserve for inventory obsolescence, fair value of goodwill and valuation of derivative liabilities. While the Company believes that the estimates and assumptions used in the preparation of these condensed consolidated financial statements are appropriate, actual results could differ from those estimates. Estimates and assumptions are periodically reviewed, and the effects of revisions are reflected in the consolidated financial statements in the period they are determined to be necessary.</p>
CY2022Q4	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	5400000	usd
CY2022Q4	bimi	Equity Interest Rate EquityInterestRate	0.87	pure
CY2022Q4	us-gaap	Cash Cash	40000000	cny
CY2022Q4	bimi	Return Common Shares ReturnCommonShares	80000	shares
CY2022Q4	bimi	Return Common Shares ReturnCommonShares	43600	shares
CY2023Q3	bimi	Allowance For Obsolete Inventories AllowanceForObsoleteInventories	26775	usd
CY2022Q4	bimi	Allowance For Obsolete Inventories AllowanceForObsoleteInventories	27602	usd
CY2022	us-gaap	Goodwill Impairment Loss Net Of Tax GoodwillImpairmentLossNetOfTax	5385811	usd
	us-gaap	Impairment Of Tangible Assets Other Descriptors ImpairmentOfTangibleAssetsOtherDescriptors	As a result of the impairments recognized on December 31, 2022, the remaining goodwill of the Company was related to the acquisitions of Guanzan and Zhongshan.
CY2023Q3	us-gaap	Goodwill Impaired Accumulated Impairment Loss GoodwillImpairedAccumulatedImpairmentLoss	673217	usd
	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.50	pure
CY2023Q3	bimi	Percentage Of Income Tax Examination Minimum Likelihood Of Tax Benefits Being Realized Upon Settlement PercentageOfIncomeTaxExaminationMinimumLikelihoodOfTaxBenefitsBeingRealizedUponSettlement	0.13	pure
CY2022Q4	bimi	Owner Equity Percentage OwnerEquityPercentage	0.87	pure
CY2023Q3	bimi	Return Common Shares ReturnCommonShares	36400	shares
CY2023Q3	us-gaap	Foreign Currency Exchange Rate Remeasurement1 ForeignCurrencyExchangeRateRemeasurement1	7.1798	pure
CY2022Q3	us-gaap	Foreign Currency Exchange Rate Remeasurement1 ForeignCurrencyExchangeRateRemeasurement1	7.0998	pure
CY2023Q3	bimi	Foreign Currency Exchange Rate Translations Annual Average ForeignCurrencyExchangeRateTranslationsAnnualAverage	7.0148	pure
CY2022Q3	bimi	Foreign Currency Exchange Rate Translations Annual Average ForeignCurrencyExchangeRateTranslationsAnnualAverage	6.6068	pure
CY2022Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	383317	usd
CY2020Q1	us-gaap	Share Price SharePrice	2.86
CY2020Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents	3065181	usd
CY2020Q4	us-gaap	Business Combination Contingent Consideration Asset BusinessCombinationContingentConsiderationAsset	7602181	usd
CY2020Q4	us-gaap	Assets Net AssetsNet	-687949	usd
CY2020Q4	us-gaap	Business Combination Recognized Identifiable Assets Acquired Goodwill And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet	6914232	usd
CY2023Q3	us-gaap	Other Minority Interests OtherMinorityInterests	46295	usd
	bimi	Non Controlling Equity Interest Percentage NonControllingEquityInterestPercentage	0.20	pure
CY2021Q2	us-gaap	Investment Company Committed Capital InvestmentCompanyCommittedCapital	4892293	usd
CY2020Q4	bimi	Partial Consideration Paid Amount PartialConsiderationPaidAmount	20000000	cny
CY2020Q4	bimi	Partial Consideration Paid Amount PartialConsiderationPaidAmount	3096119	usd
CY2021Q1	bimi	Partial Consideration PartialConsideration	40037	usd
CY2023Q3	us-gaap	Excess Stock Shares Authorized ExcessStockSharesAuthorized	39037	shares
CY2023Q3	us-gaap	Stock Repurchase Program Remaining Number Of Shares Authorized To Be Repurchased StockRepurchaseProgramRemainingNumberOfSharesAuthorizedToBeRepurchased	1000	shares
CY2021Q2	us-gaap	Stockholders Equity Other Shares StockholdersEquityOtherShares	80000	shares
CY2021Q2	us-gaap	Stockholders Equity Other StockholdersEquityOther	78000000	cny
CY2021Q2	us-gaap	Stockholders Equity Other StockholdersEquityOther	12000000	usd
CY2021Q2	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	84000000	cny
CY2021Q2	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	13008734	usd
CY2022Q4	bimi	Equity Method Investments Summarized Financial Information Minority Interest EquityMethodInvestmentsSummarizedFinancialInformationMinorityInterest	0.90	pure
CY2022Q4	us-gaap	Stockholders Equity Other Shares StockholdersEquityOtherShares	80000	shares
CY2022Q4	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	20000000	cny
CY2022Q4	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	2767860	usd
CY2022Q4	bimi	Common Stock Returned Shares CommonStockReturnedShares	43600	shares
CY2023Q3	bimi	Common Stock Returned Shares CommonStockReturnedShares	36400	shares
CY2023Q3	us-gaap	Business Combination Contingent Consideration Asset Current BusinessCombinationContingentConsiderationAssetCurrent	1498200	usd
CY2023Q3	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	573458	usd
	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	924742	usd
CY2022Q4	bimi	Common Stock Shares Amount CommonStockSharesAmount	44000	shares
CY2022Q3	bimi	Equity Interests Percentage EquityInterestsPercentage	1	pure
CY2022Q3	us-gaap	Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountIncludingPortionAttributableToNoncontrollingInterests	180000	usd
CY2022Q3	bimi	Share Issued Payment ShareIssuedPayment	270000	shares
CY2023Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	5000000	shares
CY2023Q2	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	5000000	shares
	bimi	Consideration Value Of Shares ConsiderationValueOfShares	270000	shares
	us-gaap	Income Loss From Subsidiaries Net Of Tax IncomeLossFromSubsidiariesNetOfTax	259636	usd
CY2023Q3	us-gaap	Loss On Contract Termination LossOnContractTermination	30131	usd
CY2023Q3	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1	827	pure
CY2023Q3	bimi	Inventory Reserves InventoryReserves	26775	usd
CY2022Q4	bimi	Inventory Reserves InventoryReserves	27602	usd
	bimi	Accrued Allowance Of Inventory AccruedAllowanceOfInventory	26775	usd
	bimi	Accrued Allowance Of Inventory AccruedAllowanceOfInventory	27077	usd
	us-gaap	Salaries And Wages SalariesAndWages	475217	usd
	us-gaap	Proceeds From Issuance Of Long Term Debt And Capital Securities Net ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet		usd
CY2023Q3	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	8019335	usd
CY2022Q4	us-gaap	Accounts Receivable Gross Current AccountsReceivableGrossCurrent	4813160	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	3903371	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	1604874	usd
CY2023Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	4115964	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3208286	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1604874	usd
CY2022Q1	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	322145	usd
	us-gaap	Loans And Leases Receivable Related Parties Additions LoansAndLeasesReceivableRelatedPartiesAdditions	2298497	usd
	us-gaap	Loans And Leases Receivable Related Parties Additions LoansAndLeasesReceivableRelatedPartiesAdditions	1282729	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	3903371	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	1604874	usd
CY2022Q4	us-gaap	Goodwill Gross GoodwillGross	2065666	usd
	us-gaap	Payments To Suppliers PaymentsToSuppliers	8737956	usd
CY2022	us-gaap	Payments To Suppliers PaymentsToSuppliers	6589759	usd
CY2023Q3	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	6579144	usd
CY2022Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	7067613	usd
CY2023Q3	bimi	Healthcare Products HealthcareProducts	319075	usd
CY2023Q3	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	215347	usd
CY2022Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	614231	usd
CY2023Q3	bimi	Less Impairment Allowance LessImpairmentAllowance	-26775	usd
CY2022Q4	bimi	Less Impairment Allowance LessImpairmentAllowance	-27602	usd
CY2023Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	7086791	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	7654242	usd
CY2022Q4	bimi	Inventory Reserves InventoryReserves	27602	usd
CY2021Q4	bimi	Inventory Reserves InventoryReserves	103178	usd
CY2022	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge	75576	usd
CY2023Q3	bimi	Rental Security Deposits RentalSecurityDeposits	124749	usd
CY2022Q4	bimi	Rental Security Deposits RentalSecurityDeposits	132960	usd
CY2023Q3	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	54438	usd
CY2022Q4	us-gaap	Other Prepaid Expense Current OtherPrepaidExpenseCurrent	56121	usd
CY2022	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired	180000	usd
	us-gaap	Increase Decrease In Earnest Money Deposits Outstanding IncreaseDecreaseInEarnestMoneyDepositsOutstanding	147560	usd
CY2022	us-gaap	Increase Decrease In Earnest Money Deposits Outstanding IncreaseDecreaseInEarnestMoneyDepositsOutstanding	166765	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	21533	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	24337	usd
CY2023Q3	us-gaap	Unsecured Debt Current UnsecuredDebtCurrent	87048	usd
CY2022Q4	us-gaap	Unsecured Debt Current UnsecuredDebtCurrent	66986	usd
CY2023Q3	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	830193	usd
CY2022Q4	us-gaap	Value Added Tax Receivable ValueAddedTaxReceivable	881014	usd
CY2023Q3	us-gaap	Other Payables To Broker Dealers And Clearing Organizations OtherPayablesToBrokerDealersAndClearingOrganizations	29191	usd
CY2022Q4	us-gaap	Other Payables To Broker Dealers And Clearing Organizations OtherPayablesToBrokerDealersAndClearingOrganizations	42771	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	16376	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Premiums And Other Receivables AllowanceForDoubtfulAccountsPremiumsAndOtherReceivables	23875	usd
CY2023Q3	us-gaap	Premiums And Other Receivables Net PremiumsAndOtherReceivablesNet	1278336	usd
CY2022Q4	us-gaap	Premiums And Other Receivables Net PremiumsAndOtherReceivablesNet	1527079	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Noncurrent AllowanceForDoubtfulAccountsReceivableNoncurrent	23875	usd
CY2021Q4	us-gaap	Allowance For Doubtful Accounts Receivable Noncurrent AllowanceForDoubtfulAccountsReceivableNoncurrent	26080	usd
	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	-7499	usd
CY2022	us-gaap	Provision For Loan Losses Expensed ProvisionForLoanLossesExpensed	-2205	usd
CY2023Q3	us-gaap	Allowance For Doubtful Accounts Receivable Noncurrent AllowanceForDoubtfulAccountsReceivableNoncurrent	16376	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Noncurrent AllowanceForDoubtfulAccountsReceivableNoncurrent	23875	usd
	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	16376	usd
	us-gaap	Allowance For Doubtful Accounts Receivable Period Increase Decrease AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease	23420	usd
CY2021Q4	us-gaap	Goodwill Gross GoodwillGross	8376217	usd
CY2022	bimi	Disposal Of Zhuoda DisposalOfZhuoda	924740	usd
CY2022	us-gaap	Goodwill Impairment Loss Net Of Tax GoodwillImpairmentLossNetOfTax	5385811	usd
CY2023Q3	us-gaap	Goodwill Goodwill	2065666	usd
CY2022Q4	us-gaap	Goodwill Goodwill	2065666	usd
CY2022	us-gaap	Goodwill Transfers GoodwillTransfers	1392449	usd
CY2023Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2581496	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2642346	usd
CY2023Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	909868	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	938926	usd
CY2023Q3	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	1671628	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	1703420	usd
	us-gaap	Depreciation Depreciation	73752	usd
	us-gaap	Depreciation Depreciation	86111	usd
CY2023Q3	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	6233	usd
CY2022Q4	us-gaap	Capitalized Computer Software Gross CapitalizedComputerSoftwareGross	19679	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	500000	usd
CY2023Q3	bimi	H Less Accumulated Amortization HLessAccumulatedAmortization	-38070	usd
CY2022Q4	bimi	H Less Accumulated Amortization HLessAccumulatedAmortization	-3496	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	468163	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	16183	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	37500	usd
	us-gaap	Goodwill Transfers GoodwillTransfers	673217	usd
CY2023Q3	bimi	Operating Lease Right Of Use Asset Total OperatingLeaseRightOfUseAssetTotal	2907606	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	2574751	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	809424	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	830940	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	785644	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	757958	usd
CY2023Q3	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFive	320075	usd
	bimi	Total Minimum Lease Payments TotalMinimumLeasePayments	3504041	usd
	bimi	Less Amounts Representing Interest LessAmountsRepresentingInterest	-330672	usd
CY2023Q3	bimi	Operating Lease Total OperatingLeaseTotal	3173369	usd
CY2022	us-gaap	Salaries And Wages SalariesAndWages	411043	usd
CY2023Q3	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2360333	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2135333	usd
CY2023Q3	bimi	Accrued Operating Expenses AccruedOperatingExpenses	-900	usd
CY2023Q3	us-gaap	Short Term Borrowings ShortTermBorrowings	1136522	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	818425	usd
	us-gaap	Interest Expense Short Term Borrowings InterestExpenseShortTermBorrowings	35354	usd
	us-gaap	Interest Expense Short Term Borrowings InterestExpenseShortTermBorrowings	35743	usd
CY2023Q2	us-gaap	Other Borrowings OtherBorrowings	348199	usd
	bimi	Interest Rate Description InterestRateDescription	The loan is due on May 20, 2024, with an interest rate of 8.91%.
CY2023Q3	us-gaap	Other Borrowings OtherBorrowings	105853	usd
CY2023Q1	us-gaap	Debt Conversion Converted Instrument Expiration Or Due Date Day Month And Year DebtConversionConvertedInstrumentExpirationOrDueDateDayMonthAndYear	2024-03-21
CY2022Q4	us-gaap	Other Long Term Debt OtherLongTermDebt	682470	usd
CY2023Q3	us-gaap	Other Loans Payable OtherLoansPayable	160183	usd
CY2022Q4	us-gaap	Other Loans Payable OtherLoansPayable	420751	usd
CY2023Q3	us-gaap	Long Term Debt Current LongTermDebtCurrent	135809	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	105965	usd
CY2023Q3	us-gaap	Long Term Loans Payable LongTermLoansPayable	24374	usd
CY2022Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	314786	usd
	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	29507	usd
	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	51682	usd
CY2022Q3	us-gaap	Other Long Term Debt OtherLongTermDebt	912500	usd
CY2022Q3	us-gaap	Long Term Debt Term LongTermDebtTerm	P2Y
CY2022Q3	us-gaap	Long Term Debt Percentage Bearing Variable Interest Rate LongTermDebtPercentageBearingVariableInterestRate	0.144	pure
CY2021Q4	us-gaap	Other Long Term Debt OtherLongTermDebt	148571	usd
CY2023Q3	us-gaap	Long Term Debt Percentage Bearing Variable Interest Rate LongTermDebtPercentageBearingVariableInterestRate	0.1296	pure
CY2022Q2	us-gaap	Other Long Term Debt OtherLongTermDebt	300000	usd
CY2021Q3	us-gaap	Other Long Term Debt OtherLongTermDebt	39839	usd
CY2021Q3	us-gaap	Long Term Debt Term LongTermDebtTerm	P2Y
CY2021Q3	us-gaap	Long Term Debt Percentage Bearing Variable Interest Rate LongTermDebtPercentageBearingVariableInterestRate	0.1368	pure
CY2021Q1	us-gaap	Other Long Term Debt OtherLongTermDebt	243154	usd
CY2021Q1	us-gaap	Long Term Debt Term LongTermDebtTerm	P3Y
CY2021Q1	us-gaap	Long Term Debt Percentage Bearing Variable Interest Rate LongTermDebtPercentageBearingVariableInterestRate	0.08	pure
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	3592	usd
CY2023Q3	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	599	usd
CY2023Q3	us-gaap	Long Term Debt LongTermDebt	4191	usd
CY2020Q2	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	6550000	usd
CY2020Q2	bimi	Discount Rate DiscountRate	0.1985	pure
CY2023Q3	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	142.25
CY2021Q1	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	129.5
	us-gaap	Stockholders Equity Note Stock Split StockholdersEquityNoteStockSplit	The Company implemented a reverse stock split on February 2, 2022, at the ratio of 5 to 1.
CY2022Q4	us-gaap	Convertible Debt Current ConvertibleDebtCurrent	1108785	usd
CY2022Q4	us-gaap	Convertible Debt ConvertibleDebt	1108785	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.71	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.71	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0087	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0087	pure
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P1Y5M1D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P1Y5M1D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.78	pure
	bimi	Trading Days TradingDays	P10D
CY2022	us-gaap	Business Combination Consideration Transferred1 BusinessCombinationConsiderationTransferred1	3000	usd
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	414044	shares
CY2022Q4	bimi	Accrued Operating Expenses AccruedOperatingExpenses	-900	usd
CY2023Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	430806	usd
CY2022Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	630098	usd
CY2023Q3	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	3265456	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	3175574	usd
CY2019Q4	us-gaap	Salaries Wages And Officers Compensation SalariesWagesAndOfficersCompensation	500000	usd
CY2021Q4	bimi	Employment Agreement Term EmploymentAgreementTerm	P1Y
CY2021Q4	bimi	Salaries And Wage SalariesAndWage	1000000	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod	100000	shares
	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	300000	usd
CY2021Q3	us-gaap	Deferred Compensation Arrangement With Individual Compensation Expense DeferredCompensationArrangementWithIndividualCompensationExpense	250000	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Noncurrent AccountsPayableAndAccruedLiabilitiesNoncurrent	265833	usd
	bimi	Unpaid Cash Of Salary UnpaidCashOfSalary	1000000	usd
CY2023Q3	us-gaap	Other Receivables Gross Current OtherReceivablesGrossCurrent	6964	usd
CY2023Q3	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	524195	usd
CY2022Q4	us-gaap	Accounts Payable Current And Noncurrent AccountsPayableCurrentAndNoncurrent	2980441	usd
CY2023Q3	us-gaap	Longterm Construction Loan Current And Noncurrent LongtermConstructionLoanCurrentAndNoncurrent	27699	usd
	us-gaap	Professional Fees ProfessionalFees	248690	usd
	us-gaap	Interest Income Interest Earning Asset InterestIncomeInterestEarningAsset	172730	usd
CY2022Q4	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	2000000	usd
CY2022Q4	us-gaap	Investment Interest Rate InvestmentInterestRate	0.06	pure
CY2022	bimi	Closing Price Percentage Of Common Stock ClosingPricePercentageOfCommonStock	0.60	pure
CY2022	us-gaap	Common Stock Convertible Conversion Price Decrease CommonStockConvertibleConversionPriceDecrease	0.25
CY2022	us-gaap	Conversion Of Stock Shares Issued1 ConversionOfStockSharesIssued1	1330000	shares
CY2022Q3	us-gaap	Registration Payment Arrangement Maximum Potential Consideration RegistrationPaymentArrangementMaximumPotentialConsideration	5000000	usd
CY2023Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	3000000	usd
CY2023Q1	us-gaap	Investment Company Purchase Premium Per Share InvestmentCompanyPurchasePremiumPerShare	1.5
CY2023Q3	bimi	Cash Received CashReceived	1600000	usd
CY2022Q3	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	2500000	usd
CY2022Q4	us-gaap	Loans And Leases Receivable Net Reported Amount LoansAndLeasesReceivableNetReportedAmount	500000	usd
CY2023Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6673006	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	3764780	shares
CY2021Q1	bimi	Aggregate Principal Amounts AggregatePrincipalAmounts	74473	usd
CY2023Q3	bimi	Shares Return SharesReturn	39037	shares
CY2022Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	10000	shares
CY2022	bimi	Aggregate Principals Amount AggregatePrincipalsAmount	2097000	usd
CY2022	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	1138248	shares
CY2022Q4	bimi	Common Stock Shares CommonStockShares	1234715	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	44445	shares
CY2022Q4	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	2000000	usd
CY2023Q3	us-gaap	Shares Issued SharesIssued	2420	shares
CY2023Q3	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	3000	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized	891762	shares
	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	414044	shares
	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-1146581	usd
	us-gaap	Net Income Loss From Continuing Operations Available To Common Shareholders Basic NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersBasic	-12214648	usd
	us-gaap	Net Income Loss From Discontinued Operations Available To Common Shareholders Basic NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic	-259820	usd
	us-gaap	Net Income Loss From Discontinued Operations Available To Common Shareholders Basic NetIncomeLossFromDiscontinuedOperationsAvailableToCommonShareholdersBasic	-957203	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-1406401	usd
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-13171851	usd
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	4967278	shares
	us-gaap	Weighted Average Number Of Shares Issued Basic WeightedAverageNumberOfSharesIssuedBasic	24037736	shares
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.23
	us-gaap	Income Loss From Continuing Operations Per Basic Share IncomeLossFromContinuingOperationsPerBasicShare	-0.51
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-0.05
	us-gaap	Discontinued Operation Income Loss From Discontinued Operation Net Of Tax Per Basic Share DiscontinuedOperationIncomeLossFromDiscontinuedOperationNetOfTaxPerBasicShare	-0.04
	bimi	Total Loss Per Share TotalLossPerShare	-0.28
	bimi	Total Loss Per Share TotalLossPerShare	-0.55
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	11278496	usd
	bimi	Cost Of Revenues CostOfRevenues	6589020	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	111252	usd
	bimi	Profitloss Profitloss	-1146581	usd
CY2023Q3	bimi	Total Assets TotalAssets	29517638	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	10476224	usd
	bimi	Cost Of Revenues CostOfRevenues	8928138	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	86111	usd
	bimi	Profitloss Profitloss	-12214648	usd
CY2022Q3	bimi	Total Assets TotalAssets	25155283	usd
	us-gaap	Payments To Acquire Land Held For Use PaymentsToAcquireLandHeldForUse		usd
	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
	bimi	Net Proceeds From Stock Purchase NetProceedsFromStockPurchase		usd
	bimi	Schedule Of Revenues From Each Types Of Products Table Txet Block ScheduleOfRevenuesFromEachTypesOfProductsTableTxetBlock	For the nine months ended September 30, 2023 and 2022, respectively, the Company reported revenues for each segment as follows:<table cellpadding="0" cellspacing="0" style="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif"> <tr style="vertical-align: bottom"> <td style="text-align: center"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="6" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">For the nine months ended<br/> September 30,</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2023</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1.5pt"> </td> <td colspan="2" style="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid">2022</td><td style="padding-bottom: 1.5pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 76%; text-align: left; text-indent: -9pt; padding-left: 9pt">Medical devices</td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">1,399,622</td><td style="width: 1%; text-align: left"> </td><td style="width: 1%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 9%; text-align: right">3,404,533</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Healthcare products</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,319,657</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><div style="-sec-ix-hidden: hidden-fact-124">-</div></td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; text-indent: -9pt; padding-left: 9pt">Wholesale pharmaceuticals</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,091,937</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,453,109</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1.5pt; text-indent: -9pt; padding-left: 9pt">Pharmacy retail</td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">467,280</td><td style="padding-bottom: 1.5pt; text-align: left"> </td><td style="padding-bottom: 1.5pt"> </td> <td style="border-bottom: Black 1.5pt solid; text-align: left"> </td><td style="border-bottom: Black 1.5pt solid; text-align: right">618,582</td><td style="padding-bottom: 1.5pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 4pt; text-indent: -9pt; padding-left: 9pt">Total</td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">11,278,496</td><td style="padding-bottom: 4pt; text-align: left"> </td><td style="padding-bottom: 4pt"> </td> <td style="border-bottom: Black 4pt double; text-align: left">$</td><td style="border-bottom: Black 4pt double; text-align: right">10,476,224</td><td style="padding-bottom: 4pt; text-align: left"> </td></tr> </table>
	bimi	Total Revenue TotalRevenue	11278496	usd
	bimi	Total Revenue TotalRevenue	10476224	usd
	bimi	Cost Of Revenues1 CostOfRevenues1	5308005	usd
	bimi	Percentage Of Total Revenue PercentageOfTotalRevenue	0.4706	pure
	bimi	Shares Of Common Stock Were Returned SharesOfCommonStockWereReturned	1000	shares
CY2023Q3	bimi	Common Stock Returned CommonStockReturned	36400	shares
	us-gaap	Dividends Sharebased Compensation Stock DividendsSharebasedCompensationStock	3000000	usd
CY2023Q3	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	1.5
CY2022Q3	us-gaap	Stock Issued During Period Shares Issued For Services StockIssuedDuringPeriodSharesIssuedForServices	5000000	shares
	bimi	Aggregate Amount AggregateAmount	2500000	usd
	dei	Document Period End Date DocumentPeriodEndDate	2023-09-30
CY2022Q4	us-gaap	Other Receivables OtherReceivables		usd
CY2023Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent		usd
CY2023Q3	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium		usd
	us-gaap	Investment Income Net Amortization Of Discount And Premium InvestmentIncomeNetAmortizationOfDiscountAndPremium		usd
CY2023Q3	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
	us-gaap	Other Nonoperating Income OtherNonoperatingIncome		usd
CY2023Q3	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q3	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.09
	us-gaap	Income Loss From Continuing Operations Per Diluted Share IncomeLossFromContinuingOperationsPerDilutedShare	-0.23
CY2023Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.02
CY2022Q3	us-gaap	Income Loss From Discontinued Operations Net Of Tax Per Diluted Share IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare	-0.02
	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts		usd
	us-gaap	Gain Or Loss On Sale Of Stock In Subsidiary GainOrLossOnSaleOfStockInSubsidiary		usd
	us-gaap	Cash Provided By Used In Financing Activities Discontinued Operations CashProvidedByUsedInFinancingActivitiesDiscontinuedOperations		usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid		usd
	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1		usd
	bimi	Issuance Of Common Stock Upon Conversion Of Convertible Notes IssuanceOfCommonStockUponConversionOfConvertibleNotes		usd
CY2023Q3	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet		usd
CY2022Q4	us-gaap	Accounts And Notes Receivable Net AccountsAndNotesReceivableNet		usd
CY2023Q3	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable		usd
CY2022Q4	bimi	Healthcare Products HealthcareProducts		usd
	us-gaap	Inventory Lifo Reserve Period Charge InventoryLIFOReservePeriodCharge		usd
CY2022Q4	us-gaap	Foreign Currency Exchange Rate Translation1 ForeignCurrencyExchangeRateTranslation1		pure
	us-gaap	Fair Value Of Assets Acquired FairValueOfAssetsAcquired		usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross		usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets		usd
	bimi	Disposal Of Zhuoda DisposalOfZhuoda		usd
	us-gaap	Goodwill Impairment Loss Net Of Tax GoodwillImpairmentLossNetOfTax		usd
CY2023Q3	us-gaap	Convertible Debt Current ConvertibleDebtCurrent		usd
CY2023Q3	us-gaap	Convertible Debt ConvertibleDebt		usd
CY2023Q3	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Units StockIssuedDuringPeriodValueConversionOfUnits		usd
CY2022Q4	us-gaap	Other Receivables OtherReceivables		usd
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	24037736	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4967278	shares
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Central Index Key EntityCentralIndexKey	0001213660

Files In Submission

Name	View Source	Status
0001213900-23-096651-index-headers.html	Edgar Link	pending
0001213900-23-096651-index.html	Edgar Link	pending
0001213900-23-096651.txt	Edgar Link	pending
0001213900-23-096651-xbrl.zip	Edgar Link	pending
bimi-20230930.xsd	Edgar Link	pending
f10q0923ex31-1_bimiinter.htm	Edgar Link	pending
f10q0923ex31-2_bimiinter.htm	Edgar Link	pending
f10q0923ex32-1_bimiinter.htm	Edgar Link	pending
f10q0923ex32-2_bimiinter.htm	Edgar Link	pending
f10q0923_bimiinter.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R100.htm	Edgar Link	pending
R101.htm	Edgar Link	pending
R102.htm	Edgar Link	pending
R103.htm	Edgar Link	pending
R104.htm	Edgar Link	pending
R105.htm	Edgar Link	pending
R106.htm	Edgar Link	pending
R107.htm	Edgar Link	pending
R108.htm	Edgar Link	pending
R109.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R110.htm	Edgar Link	pending
R111.htm	Edgar Link	pending
R112.htm	Edgar Link	pending
R113.htm	Edgar Link	pending
R114.htm	Edgar Link	pending
R115.htm	Edgar Link	pending
R116.htm	Edgar Link	pending
R117.htm	Edgar Link	pending
R118.htm	Edgar Link	pending
R119.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R120.htm	Edgar Link	pending
R121.htm	Edgar Link	pending
R122.htm	Edgar Link	pending
R123.htm	Edgar Link	pending
R124.htm	Edgar Link	pending
R125.htm	Edgar Link	pending
R126.htm	Edgar Link	pending
R127.htm	Edgar Link	pending
R128.htm	Edgar Link	pending
R129.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R130.htm	Edgar Link	pending
R131.htm	Edgar Link	pending
R132.htm	Edgar Link	pending
R133.htm	Edgar Link	pending
R134.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
f10q0923_bimiinter_htm.xml	Edgar Link	completed
R135.htm	Edgar Link	pending
R136.htm	Edgar Link	pending
R137.htm	Edgar Link	pending
R138.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R89.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
R90.htm	Edgar Link	pending
R91.htm	Edgar Link	pending
R92.htm	Edgar Link	pending
R93.htm	Edgar Link	pending
R94.htm	Edgar Link	pending
R95.htm	Edgar Link	pending
R96.htm	Edgar Link	pending
R97.htm	Edgar Link	pending
R98.htm	Edgar Link	pending
R99.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
bimi-20230930_lab.xml	Edgar Link	unprocessable
bimi-20230930_pre.xml	Edgar Link	unprocessable
bimi-20230930_cal.xml	Edgar Link	unprocessable
bimi-20230930_def.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BIMI
BIMI Holdings Inc. Stock $bimi

2023 Q3 Form 10-Q Financial Statement

#000121390023096651 Filed on December 19, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIMI BIMI Holdings Inc. Stock $bimi

2023 Q3 Form 10-Q Financial Statement

#000121390023096651 Filed on December 19, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BIMI
BIMI Holdings Inc. Stock $bimi